Board and executive changes

; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 4, 2026, Taha Kass-Hout notified GE HealthCare Technologies Inc. (“GE HealthCare”) that he will resign as Chief Science and Technology Officer. Mr. Kass-Hout’s last day at GE HealthCare will be December 31, 2026.

On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses.

Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to the operations, policies or practices of AbbVie.

On October 29, 2026, the Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven members and appointed Aaron Martin to fill the resulting vacancy, effective as of January 1, 2027. Mr. Martin will not be appointed to any committees as of the effective date. The Board has determined that Mr. Martin is an independent director under applicable rules of the Nasdaq Stock Market (“Nasdaq”) and the U.S. Securities and Exchange Commission. Pursuant to the Company’s standard compensation program for its non-employee directors, Mr. Martin will receive an annual cash retainer of $70,000 for service as a member of the Board, which amount will be prorated for the portion of the fiscal year remaining following the effective date of his appointment. Mr.

On October 27, 2026, Thermo Fisher Scientific Inc. (the “Company”), announced that Michael D. Shafer, Executive Vice President of the Company, will retire effective December 31, 2026. 2

On October 22, 2026, Jeannette Bankes notified GE HealthCare that she will resign as President and CEO, Patient Care Solutions. Ms. Bankes' last day at GE HealthCare will be November 15, 2026.

CEO Succession and Appointment of New Director On October 26, 2026, the Board of Directors (the “ Board ”) of Align Technology, Inc. (the “ Company ”) appointed Jennifer L. Davis as Chief Executive Officer-elect and director of the Company, effective November 2, 2026 (the “ Commencement Date ”), and as President and Chief Executive Officer (“ CEO ”) of the Company, effective December 31, 2026. Joseph M. Hogan will continue to serve as the Company’s President and CEO through December 31, 2026, at which time he will retire and begin serving as a strategic advisor to the Company under the terms of an Executive Consulting Agreement, executed October 27, 2026 (the “ Hogan Consulting Agreement ”). During the transition period from November 2, 2026 through December 31, 2026, Ms. Davis will work with Mr.

Departure of President and Chief Executive Officer On October 27, 2026, Albert G. White III resigned from the Board of Directors (the “Board”) of The Cooper Companies, Inc. (the “Company”) and he ceased serving in the offices of President and Chief Executive Officer of the Company. Mr. White has agreed to remain employed full time as a strategic advisor to the Company through April 1, 2027 to assist in the transition of his responsibilities. Mr. White will receive the payments and benefits to which he is entitled under his Executive Employment Agreement with the Company, dated March 19, 2024, as described under the caption “Quantification of Potential Payments” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on February 24, 2026 (the “Proxy Statement”), which description is incorporated herein by reference.

(d) Election of Directors. On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately. Mr. Gibbs served as Chief Executive Officer of Yum! Brands, Inc., a leading global restaurant company, from 2020 to September 2025 and as a director of Yum! Brands from 2019 to September 2025. Since October 2025, Mr. Gibbs has served as an advisor to Yum! Brands. Previously, he served as President and Chief Operating Officer of Yum! Brands from August 2019 to December 2019; President, Chief Operating Officer and Chief Financial Officer from January 2019 to August 2019; and President and Chief Financial Officer from 2016 to 2018. Earlier in his career at Yum! Brands, Mr. Gibbs served as Chief Executive Officer of the Pizza Hut Division from 2015 to 2016, President of Pizza Hut U.S.

(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee. Mr. Brennan served as the Executive Vice President, Chief Financial Officer of Boston Scientific Corporation, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025. He was the Senior Vice President, Corporate Controller from 2010 through 2013 and, prior to that role, he held various roles of increasing responsibility within the finance function from 1996 through 2009. Mr.

On October 15, 2026, the Board of Directors (the "Board") of Medtronic plc (the “Company”) approved the appointment of Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations to the role of President, Medtronic, effective October 14, 2026. In this expanded role, Mr. Marinaro will continue with his current responsibilities, in addition to exercising oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu, Senior Vice President and President, Greater China. Mr. Marinaro will continue to report to Geoffrey S. Martha, who will continue to serve as the Company’s Chairman of the Board of Directors and Chief Executive Officer. In connection with Mr.

Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves as the Vice Chancellor for Health Sciences at the University of California San Diego and was previously a director of Avantor, Inc. Dr. Carethers has been appointed to the Public Policy and Sustainability Committee of AbbVie. The Board affirmatively determined that Dr. Carethers is an “independent director” under each of the standards set forth in section 303A.02 of the New York Stock Exchange Listed Company Manual and AbbVie’s Governance Guidelines and Director Independence Guidelines. Dr.

On October 8, 2026, the Board of Directors (the "Board") of Zoetis Inc. (the “Company”) appointed Iris Knobloch to the Board, effective as of December 1, 2026, to serve in such capacity until her successor is appointed or qualified or until her resignation or removal. In connection with the appointment of Ms. Knobloch, the size of the Board will be increased from twelve to thirteen members effective as of December 1, 2026. Ms. Knobloch has been appointed to serve on the Board’s Corporate Governance Committee. Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between the Company and Ms. Knobloch that would be reportable under Item 404(a) of Regulation S-K.

Director Appointments On October 9, 2026, the Board of Directors (the “Board”) of Danaher Corporation (the “Company” or “Danaher”) increased the size of the Board to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg to the Board, in each case effective immediately. Each of Mr. Comas and Dr. Hershberg will serve until the Company’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Dr. Hershberg has also been appointed to serve as a member of the Science and Technology Committee of the Board. Daniel L. Comas, age 62, joined the Company in 1991 and served as Executive Vice President from April 2005 through December 2020, including as Chief Financial Officer from April 2005 through December 2018. During his tenure, Mr.

(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on October 13, 2026, attached as Exhibit 99.1, announcing the election of Paul J. Diaz to the Company’s Board of Directors (the “Board”), effective November 1, 2026. The Board appointed Mr. Diaz as a member of both the Audit Committee and the Research Committee of the Board. For his service on the Board, Mr. Diaz will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 8, 2026. Mr.

On October 6, 2026, Donna F. Zarcone informed the Board of Directors (the “Board”) of The Cigna Group (the “Company”) that she will retire from the Board effective December 31, 2026. Ms. Zarcone’s retirement is not the result of any disagreement with the Company.

On October 8, 2026, Henry Schein, Inc. (the “Company”) announced that (i) Ronald N. South will continue to serve as Senior Vice President and Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer through November 3, 2026, including through the completion of the Company’s third quarter earnings process, and effective November 4, 2026, Mr. South’s employment will transition to the role of Senior Advisor and (ii) the Board of Directors (the “Board”) approved the appointment of Emmanuel Caprais to initially serve as Senior Financial Advisor of the Company on October 12, 2026, allowing for a structured transition and onboarding period, and effective November 4, 2026 to serve as Senior Vice President, Chief Financial Officer of the Company and as the Company’s principal financial officer and principal accounting officer.

Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027. Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company’s Cardiovascular business. In his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies for health care professionals and patients globally. Prior to that, Mr.

Stryker Corporation (the “Company”) announced on October 6, 2026 that Kevin A. Lobo will resign from his role as Chief Executive Officer (“CEO”) of the Company on December 31, 2026 and transition to the role of Executive Chair of the Board of Directors of the Company (the “Board”), effective January 1, 2027 (the “CEO Transition”) and that Spencer S. Stiles, who currently serves as President and Chief Operating Officer of the Company, has been appointed CEO of the Company, effective January 1, 2027. In connection with Mr. Stiles’s appointment as CEO, the Board also increased the size of the Board from 10 to 11 and appointed Mr. Stiles to serve as a member of the Board, effective January 1, 2027. Mr. Stiles has not been appointed to any committee of the Board at this time. There are no arrangements or understandings between Mr. Stiles and any other person pursuant to which Mr.

On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027. Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, the Company’s multi-year project to modernize its “Order to Cash” business processes, which includes the related information technology infrastructure and underlying enabling technologies. In connection with this transition, the Company’s Compensation and Leadership Development Committee (the “Committee”) approved no change to Ms. Doherty’s annual base salary of $650,000 or annual incentive compensation under the Company's Senior Management Incentive Plan with a target amount of 80% of base salary.

(b) and (c) On September 30, 2026, Moderna, Inc. (“Moderna” or the “Company”) announced the appointment of Juan Andres as its Chief Operating Officer (“COO”) effective October 5, 2026. In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company’s Executive Committee. Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023.

1.     New Equity Awards for CEO and CSO Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated Regeneron Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (the “ Equity Plan ”) to each of Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of the Company (“ CEO ”), and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of the Company (“ CSO ”), as described below.

Director Appointment On September 24, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Robert E. Sanchez to serve on the Board (the “Appointment”), effective October 1, 2026 (the “Effective Date”). In connection with the Appointment, the Board increased from ten to eleven members in accordance with the Company’s Amended and Restated Bylaws. Mr. Sanchez will receive the same benefits and compensation as the other non-employee directors on the Board pursuant to the Company’s Compensation Policy for Non-Employee Directors, as described on pages 40 to 41 of the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on January 22, 2026.

On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the “Retirement Date”). As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date. The Company expects to enter into a Retirement Agreement with Mr. Butcher effective as of the Retirement Date, pursuant to which Mr. Butcher will be entitled to payments and benefits that are materially consistent with those Mr.

On September 22, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. The Board also appointed Mr. Desroches as a member of the Audit Committee and the Talent, Culture, and Compensation Committee of the Board, effective January 4, 2027. Upon joining the Board, Mr. Desroches will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 19, 2026. The Company will also enter into an indemnification agreement with Mr. Desroches.

Adoption of Nonqualified Deferred Compensation Plan On September 14, 2026, the Talent and Compensation Committee (the "Committee") of the Board of Directors (the "Board") of Insulet Corporation (the "Company") approved and adopted the Insulet Nonqualified Deferred Compensation Plan (the "Plan"), with such Plan to be effective on January 1, 2027. The Plan is intended to be an unfunded "top hat" deferred compensation plan that allows a select group of management or highly compensated employees within the meaning of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), including the Company’s named executive officers, to voluntarily defer compensation in a manner intended to comply with Section 409A of the Internal Revenue Code of 1986, as amended (the "Code").

On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jereme Sylvain, the Company’s EVP, Chief Financial Officer, to the role of EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with Mr. Sylvain’s promotion, on September 11, 2026, Mr. Sylvain entered into an offer letter with the Company (the “Offer Letter”) providing for an annual base salary of $767,000 and annual target bonus opportunity equal to 75% of his base salary. Mr. Sylvain remains eligible to receive annual equity awards under the Company’s Amended and Restated 2015 Equity Incentive Plan, to participate in the Company’s Amended and Restated Severance & Change in Control Plan as an executive officer, and to participate in the employee benefit plans that Dexcom offers to its other employees.

On September 3, 2026, Timothy J. Scannell, a member of the Board of Directors (the "Board") of Insulet Corporation (the "Company"), notified the Company of his decision to step down from the Board for health reasons, effective September 3, 2026. The Board and management extend their sincere appreciation to Mr. Scannell for his leadership, unwavering commitment and invaluable guidance to the Company throughout his 12 years of service on the Board, including 7 years as Chairman of the Board, during which he helped guide the Company through a period of significant growth and advancement. On September 8, 2026, Michael R. Minogue also notified the Company of his decision to step down from the Board to focus on his candidacy for Governor of Massachusetts, effective September 15, 2026. The Board and management are grateful to Mr.

On September 10, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to thirteen directors and appointed Glenn S. Boehnlein as a director, effective immediately. Mr. Boehnlein will hold office for a term expiring at the 2027 annual meeting of Dexcom’s stockholders (the “2027 Annual Meeting”). The Board also appointed Mr. Boehnlein to serve as a member of the Operations & Innovation Committee and the Audit Committee of the Board, effective immediately. There is no arrangement or understanding between Mr. Boehnlein and any other persons pursuant to which Mr. Boehnlein was selected as a director. Mr.

On September 8, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) notified Kevin Thornal, Group President, Global Businesses and the Americas, that his position is being restructured. Mr. Thornal will be departing from the Company, effective on September 30, 2026. Mr. Thornal will be eligible for severance benefits under the Company’s Restated Executive Severance Plan, as amended (the “Severance Plan”). Pursuant to the Severance Plan, Mr. Thornal will receive benefits, including a lump sum amount equal to the sum of twelve months of his annual base salary plus target annual bonus, plus twelve months of his current monthly COBRA premiums. His right to receive such severance payments and benefits is conditioned upon his executing and not revoking a general release in favor of the Company.

(b) On September 2, 2026, Boon Hwee Koh, Chairperson of the Board of Directors (the "Board") of Agilent Technologies, Inc. (the "Company"), notified the Company of his decision to retire from the Board, effective as of September 4, 2026. Mr. Koh's decision to retire was not due to any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices. The Company and the Board thank Mr. Koh for his valuable insights, perspective, and commitment during his 23-year service on the Board. (d) On September 4, 2026, the Board upon the recommendation of its Nominating/Corporate Governance Committee, appointed Glenn Boehnlein, to fill the vacancy created by the resignation of Mr. Koh, effective September 4, 2026 to serve as a Class III director, the class of directors that will stand for re-election at the 2027 Annual Meeting of Stockholders.

On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with Mr. Poole’s appointment, Charles F. Wagner, Jr., the Company’s Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer. Mr. Poole, 51, has been Senior Vice President, Finance at the Company since March 2020. Previously, Mr. Poole served as Chief Financial Officer of Evelo Biosciences, Inc. from March 2018 to March 2020 and as Chief Financial Officer of Genocea Biosciences, Inc. from April 2014 to March 2018. Earlier in his career, Mr.

Appointment of Quentin Blackford On August 27, 2026, the Board of Directors (the “Board”) of Align Technology, Inc. (the “Company”) appointed Quentin Blackford, 48, to the Board. In connection with Mr. Blackford’s appointment, the Board increased the size of the Board from ten to eleven directors. The Company expects Mr. Blackford to stand for election at the next annual meeting of stockholders, which is expected to be held in May 2027. Mr.

The Board of Directors of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, of his decision to retire from the Company by mid-year 2027. A selection process will begin promptly to identify a successor, which is expected to result in a transition of duties during 2027. Mr. Bobo is also expected to remain as a consultant with the Company through the end of 2027. 2

(b) On August 17, 2026, Robert L. Carpio III notified Waters Corporation (the “Company”) of his decision to resign from his position as Senior Vice President, Waters Analytical Sciences Division to pursue other opportunities. Mr. Carpio relinquished his duties related to such position effective August 20, 2026.

On August 20, 2026, Veeva Systems Inc. (“Veeva”) announced the appointment of Dan Rizzo to serve as EVP, Sales, Consulting, and Services, effective October 2, 2026. Mr. Rizzo succeeds Thomas D. Schwenger, who has been with Veeva since September 2019, most recently serving as President and Chief Customer Officer. Mr. Schwenger informed Veeva of his decision to resign on August 18, 2026 and his resignation is effective October 2, 2026. Mr. Schwenger is departing to assume a CEO role at a long-standing Veeva partner. Veeva thanks Mr. Schwenger for his outstanding service to Veeva and its customers for the past seven years.

Appointment of John Rogers as CFO On August 18, 2026, Baxter International Inc. (the “Company”) appointed John Rogers as Executive Vice President and Chief Financial Officer (“CFO”), effective as of October 1, 2026 (the “Transition Date”). Mr. Rogers, 58, is joining the Company from Smith+Nephew plc, where he has served as CFO since 2024 after beginning with the company as CFO-designate in 2023. Before Smith+Nephew, he served as CFO of WPP plc from 2020 to 2023. Rogers previously held leadership roles with J Sainsbury plc, including as CEO of Sainsbury’s Argos from 2016 to 2019 and as CFO of Sainsbury’s from 2010 to 2016. Mr. Rogers has also served as an independent director and audit committee chair of Grab Holdings Limited since 2021 and of Travis Perkins plc between 2014 and 2021. Mr.

On August 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (“GE HealthCare”) appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026. George A. Newcomb, who currently serves as GE HealthCare’s interim Chief Financial Officer, will cease serving in that interim role on September 14, 2026, and will continue serving as GE HealthCare’s Controller and Chief Accounting Officer. Mr. Grogan, age 48, has served as Executive Vice President and Chief Financial Officer of Xylem Inc., a global water solutions company, since October 2023. Previously, Mr. Grogan served as Senior Vice President and Chief Financial Officer of IDEX Corporation, a global engineered products company, from January 2017 until September 2023. On August 13, 2026, the Talent, Culture, and Compensation Committee (the “Committee”) of the Board approved Mr.

On August 13, 2026, Ronald Taylor, a director of Resmed, informed the Board that he will not stand for election at Resmed’s 2026 annual meeting of stockholders (the “Annual Meeting”) and intends to retire from the Board, effective at the Annual Meeting, which is expected to be held on November 18, 2026. Mr. Taylor’s intention to retire is not due to any disagreement with Resmed on any matter relating to Resmed’s operations, policies or practices. In connection with Mr. Taylor’s retirement, the Board approved the appointment of Carol Burt as lead director, effective November 15, 2026.

On August 13, 2026, Larry M. Robbins notified the Board of Directors (the “Board”) of CVS Health Corporation (the “Company”) of his resignation from the Board, effective immediately. Mr. Robbins’ resignation was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. On August 17, 2026, the Board appointed Teresa Heitsenrether to the Board, effective November 18, 2026. Ms. Heitsenrether, age 61, is Executive Vice President and Chief Data & Analytics Officer of JPMorgan Chase & Co. (“JPMorgan Chase”) and is a member of JPMorgan’s Operating Committee. Prior to her current role, Ms. Heitsenrether held several senior leadership positions at JPMorgan Chase, including CEO of Securities Services and Global Head of Prime Brokerage & Equity Financing. She holds an M.B.A. from New York University and a B.S.

On August 12, 2026, Andrew Asher, Chief Financial Officer of Centene Corporation (the Company), informed the Company that he intends to retire as Chief Financial Officer effective as of December 31, 2026. Thereafter, Mr. Asher will serve as Strategic Advisor, reporting to Sarah M. London, the Company’s Chief Executive Officer, through the end of 2027, to ensure an orderly transition and to support certain strategic initiatives of the Company. On August 17, 2026, the Company announced that it has identified Christopher Neczypor as Mr. Asher’s successor to be Chief Financial Officer of the Company, with such appointment intended to be effective as of January 1, 2027. Mr.

On August 13, 2026, following the conclusion of the quarterly meeting of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Lorence H. Kim, M.D., informed the Company of his intent to resign from the Board effective immediately. Dr. Kim’s decision was made in connection with his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. and his need to devote additional time to his professional responsibilities at that company. Dr. Kim has advised the Company that his resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company thanks Dr. Kim for his dedicated service.

On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026. Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses.

The Original Form 8-K reported that the Board of Directors of the Company (the “Board”) increased its size from nine to ten members on May 5, 2026, and elected Pierre Boulud to serve as a Director effective as of that date. In accordance with the Instructions to

Appointment of James Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer On August 6, 2026, Zoetis Inc. (the “Company”) announced that James Saccaro has been appointed as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. He will serve as the principal financial officer and principal accounting officer of the Company. Mr. Saccaro, age 53, has served as Vice President and Chief Financial Officer of GE HealthCare Technologies Inc. since June 2023. He previously served as Executive Vice President and Chief Financial Officer of Baxter International Inc.

On August 4, 2026, Cardinal Health, Inc. (the “Company”) appointed Anita Zielinski as its Chief Accounting Officer of the Company, effective November 5, 2026. Ms. Zielinski will succeed Mary Scherer, who will continue to serve as Chief Accounting Officer through November 5, 2026. Ms. Zielinski will join Cardinal as Senior Vice President Finance, effective September 16. Ms. Zielinski, 52, has served as interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller of Baxter International, Inc. (“Baxter”) since March 16, 2026. Ms. Zielinski joined Baxter in February 2025 as Senior Vice President, Chief Accounting Officer and Controller. Prior to joining Baxter, Ms.

On July 31, 2026, Anita Zielinski notified Baxter International Inc. (the “Company”) of her decision to resign as the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective as of September 15, 2026, to join another company. Ms. Zielinski’s resignation was not the result of any disagreement with Company management or the Company’s board of directors relating to the Company’s operations, policies, practices, financial disclosures or accounting matters.

On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026. The Company’s related press release is attached to this Report as Exhibit 99.1.

Appointment of Julie Sawyer Montgomery as President and Chief Executive Officer On August 3, 2026, Danaher Corporation (the “Company” or “Danaher”) announced that, effective as of October 1, 2026 (the “Effective Date”), the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company (the “CEO”). The Board also appointed Ms. Sawyer Montgomery to the Board and to each of the Executive, Finance and Science & Technology Committees of the Board, in each case effective as of the Effective Date. There are no arrangements or understandings between Ms. Sawyer Montgomery and any other person pursuant to which Ms. Sawyer Montgomery was selected as an officer or director of the Company, and there are no family relationships between Ms. Sawyer Montgomery and any director or executive officer of the Company.

On July 30, 2026, the Board of Directors of Mettler-Toledo International Inc. (the "Company") appointed Natalia Shuman as a director of the Company, effective August 3, 2026, and determined Ms. Shuman qualifies as an "independent director" for purposes of the New York Stock Exchange listing standards. The Board of Directors has not yet determined on which Board committees, if any, Ms. Shuman will serve. In connection with the appointment, the Board of Directors resolved to increase its size from nine directors to ten directors, effective August 3, 2026. Ms. Shuman’s compensation for her services as a director will be consistent with that of the Company's other independent directors, as described in the Company's definitive proxy statement filed with the Securities Exchange Commission on March 18, 2026. There are no arrangements or understandings between Ms.

(b) On July 30, 2026, Henry Schein, Inc. (the “Company”) announced that, effective October 30, 2026, Michael S. Ettinger, the Company’s Executive Vice President and Chief Operating Officer, and Mark E. Mlotek, the Company’s Executive Vice President and Chief Strategic Officer, will transition out of their current roles into senior advisory roles. In connection with such transition, Mr. Ettinger and Mr. Mlotek will be entitled to receive the payments and benefits under the Company’s Executive Severance Plan, in accordance with and subject to the terms and conditions of the plan.

(d) On July 28, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from eleven to thirteen and elected Frederick J. Crawford and Paul J. Smith as directors of the Company, in each case effective on July 28, 2026. The Board of Directors has determined that Messrs. Crawford and Smith qualify as independent directors under the New York Stock Exchange’s director independence standards. Messrs. Crawford and Smith will each be compensated in accordance with the Company’s director compensation program, the components of which were disclosed in the Company’s proxy statement relating to 2026 Annual Meeting of Stockholders filed with the U.S. Securities and Exchange Commission on March 6, 2026. In accordance with this program, Messrs.

(a) On July 23, 2026, Director Kenneth Burdick notified Centene Corporation (the Company) of his resignation from the Board of Directors (the Board), including from his service on the Quality and Compliance Committee, effective July 28, 2026. His resignation was not the result of any dispute or disagreement with the Company or the Company's Board on any matter relating to the operations, policies or practices of the Company. (d) Effective July 28, 2026, the Board elected Paul Diaz to the Board to fill the vacancy created by Mr. Burdick's resignation, with a term expiring at the Company's 2027 annual meeting of stockholders. He was appointed to serve as a member of the Audit Committee and the Quality and Compliance Committee. Mr. Diaz has served as a Managing Partner at Cressey & Company, a private equity firm focusing on healthcare, since May 2025.

On July 21, 2026, James K. (Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry. Mr. Saccaro’s last day at GE HealthCare will be August 14, 2026. On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim Chief Financial Officer, effective August 14, 2026. Mr. Newcomb will continue to serve as Controller and Chief Accounting Officer. GE HealthCare has commenced a search for a permanent successor. Mr. Newcomb, age 59, served as the Controller of the healthcare business of General Electric Company (“GE”) beginning in February 2016 and was named as Controller and Chief Accounting Officer of GE HealthCare in January 2023 in connection with the spin-off of GE HealthCare from GE.

On July 19, 2026, Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Dr. Garrison will remain in his role through the end of the fiscal year to support a smooth transition. A comprehensive search is underway to identify the next President of the Medical Essentials segment. Going forward, to streamline BD's operating model, the BioPharma Systems segment will report directly to Thomas E. Polen, Chairman, CEO and President of BD.

On July 16, 2026, the Board of Directors of Solventum Corporation (the “Company”) appointed Neil Zieselman to serve as Senior Vice President, Controller and Chief Accounting Officer of the Company, effective as of August 10, 2026. Mr. Zieselman is replacing Mary Wilcox in this role in connection with her previously announced retirement and will report directly to Wayde McMillan, the Company’s Chief Financial Officer. Mr. Zieselman will function as the Company’s Principal Accounting Officer for Securities and Exchange Commission (“SEC”) reporting purposes. Mr. Zieselman, age 50, joins the Company from Surgery Partners, Inc., where he has served as its Senior Vice President, Corporate Finance and Controller since May 2022. Prior to Surgery Partners, Inc., Mr.

On July 6, 2026, Julie Coletti, Executive Vice President, Chief Legal and Regulatory Officer of Align Technology, Inc. (the “ Company ” ), resigned from the Company in order to join Illumina, Inc. as Chief Legal Officer. Her resignation is effective August 1, 2026.

(d) On July 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), appointed Michael McDonnell to the Board, effective July 8, 2026. Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He previously served as Chief Financial Officer of IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. Mr. McDonnell was appointed to serve as a Class II director of the Company, to hold office until the 2029 annual meeting of shareholders or until his earlier death, resignation or removal. Mr.

On June 29, 2026, Thomas L. Rodgers, the company’s Executive Vice President, Chief Strategy and Business Development Officer and a named executive officer, gave notice of his intention to retire from that role. His last day of employment will be August 1, 2026.

On June 23, 2026, in connection with the contemplated Merger, the Compensation Committee of the Board (the “ Compensation Committee ”) approved cash retention bonus awards to each of the Company’s current named executive officers pursuant to retention agreements (the “ Retention Agreements ”) in order to encourage the Company’s named executive officers to remain with the Company and motivate their continued strong performance until the Effective Time. The Retention Agreements became effective only upon the execution of the Merger Agreement. The Compensation Committee approved the following lump sum cash bonus amounts (the “ Retention Bonuses ”) payable to the Company’s named executive officers under the Retention Agreements: Kim Kelderman – $2,120,976; Jim Hippel – $1,541,510; William Geist – $1,161,014; Shane Bohnen – $971,097; and Steve Crouse – $910,263.

On June 24, 2026, the Board of Directors (the "Board") of Insulet Corporation (the "Company") appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026. Mr. Mazelsky will stand for election by stockholders at the Company’s 2027 Annual Meeting of Stockholders. Mr. Mazelsky has been the Executive Chair of the board of directors of IDEXX Laboratories, Inc. since May 2026. He also served at IDEXX as President and Chief Executive Officer from October 2019 to May 2026, as Interim President and Chief Executive Officer from June 2019 to October 2019, and as Executive Vice President responsible for IDEXX’s North American Companion Animal Group Commercial Organization and key elements of their innovation portfolio from August 2012 to June 2019.

On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately. Dr. Skovronsky will stand for election at the Company’s 2027 annual meeting of stockholders to serve for a one-year term commencing with such meeting. Dr. Skovronsky qualifies as an independent director under the applicable rules of The Nasdaq Stock Market and the Securities and Exchange Commission. There is no arrangement or understanding between Dr. Skovronsky and any other person pursuant to which he was selected as a director. In addition, Dr. Skovronsky is not a party to any transaction with the Company reportable under Item 404(a) of Regulation S-K under the Securities Act of 1933. Dr.

On June 17, 2026, C. Raymond Larkin, Jr. notified the Board of Directors (the “Board”) of Align Technology, Inc. (the “Company”) that he will retire as Chairman of the Board effective July 1, 2026, and as a member of the Board effective December 31, 2026. Mr. Larkin’s decision to resign from the Board effective December 31, 2026 is not because of any disagreement with the Company on any matter relating to the Company ’ s operations, policies or practices, nor was he removed for cause. Also on June 17, 2026, the Board appointed Kevin Conroy, an independent director, to succeed Mr. Larkin as Chairman of the Board, effective July 1, 2026.

Effective June 19, 2026, the Board of Directors (the Board) of Centene Corporation (the Company) increased the size of the Board from 9 to 10 and elected Lauren Tyler to the Board to fill the resulting vacancy, with a term expiring at the Company's 2027 annual meeting of stockholders. She is anticipated to serve as a member of the Audit Committee and the Compensation and Talent Committee, effective as of July 1, 2026. Ms. Tyler served for more than two decades at JPMorgan Chase & Co., a multinational banking institution. She most recently served as Executive Vice President, Global Head of Human Resources for JPMorgan Chase’s Asset & Wealth Management Division from 2015 to 2024. From 2014 to 2015, Ms. Tyler served as its Global Firmwide Chief Auditor. Prior to that, Ms. Tyler had served as its Global Firmwide Head of Investor Relations from 2009 to 2012. Ms.

On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027. Dr. Cuffe will be eligible to receive benefits according to the Company’s executive severance policy and applicable incentive plans.

On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices. In connection with Mr. Denton’s departure, the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton’s successor. Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022.

On June 15, 2026, Cencora, Inc. (the “Company”) announced that Silvana Battaglia will retire as Executive Vice President and Chief Human Resources Officer of the Company effective July 12, 2026. Ms. Battaglia will serve in an advisory capacity through the end of 2026. Ms. Battaglia’s decision to retire from her position was not the result of a disagreement on any matter related to the Company’s operations, policies or practices. Ms. Battaglia will be succeeded by Samantha L. Hammock, who will join the Company as Executive Vice President and Chief Human Resources Officer effective July 13, 2026. Ms. Hammock most recently served as Executive Vice President and Chief Human Resources Officer of Verizon Communications Inc.

On March 9, 2026, West Pharmaceutical Services, Inc. (the “Company”) filed a Current Report on Form 8-K announcing that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board”) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition. On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective August 31, 2026 (the “Start Date”), to replace Mr. Green in those roles. As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy. As of the Start Date, Lead Independent Director Robert F. Friel will become Chair of the Board. Mr.

On May 27, 2026, Cencora, Inc. (the “Company”) announced that Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company (the “Appointment”), effective June 29, 2026 (the “Effective Date”). Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously disclosed. Mr. Cleary will serve in an advisory capacity through the end of 2026. Ms. Boratto, age 59, most recently served as Chief Financial Officer of Bath & Body Works, Inc. since August 2023. Prior to that, she served as Chief Financial Officer of Opentrons Labwork Inc., a privately held life sciences company, from February 2022 to July 2023.

Effective July 1, 2026, Henry L. Charlton will transition from his role as Chief Commercial and Marketing Officer of Intuitive Surgical, Inc. (the “Company”) and begin serving as Senior Vice President of Global Business Operations of the Company. Taylor Patton, Global Senior Vice President, Endoluminal will succeed Mr. Charlton as the Company’s Chief Commercial and Marketing Officer. A copy of the Company’s press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

On May 21, 2026, the Talent Committee (the “Committee”) of the Board of Directors of Solventum Corporation (the “Company”) adopted and approved the Solventum Executive Severance Plan and Summary Plan Description (the “Severance Plan”), effective June 1, 2026. The Severance Plan provides severance payments and benefits to certain eligible employees of the Company, including executive officers, in the event of an involuntary termination of employment other than for misconduct or a voluntary termination for good reason, subject to eligibility conditions and the execution of a severance agreement, which includes a release of claims.

(b) As previously disclosed, on March 5, 2026, Rodney Gonsalves, informed the Company that he would retire from his position as the Company’s Vice President, Corporate Controller and Principal Accounting Officer, the exact date to be determined at a later time. On May 20, 2026, the Company appointed Tim Downs as the new Vice President, Chief Accounting Officer of the Company and as principal accounting officer of the Company, effective as of the first business day following the Company’s filing of the quarterly report on Form 10-Q for the quarter ended April 30, 2026 (the “Start Date”). Following the Start Date, Mr. Gonsalves will remain employed as Vice President, Finance in order to provide transitional assistance through January 2027, the exact date to be determined at a later time.

Effective May 20, 2026, Ms. Louise M. Parent retired from the Board of Directors of Zoetis Inc. (the “Company”), prior to the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”) in accordance with the Company’s director retirement policy.

Departure and Compensatory Arrangements of a Certain Officer (b) On May 18, 2026, Matthew J. Peterson, Executive Vice President of the Company and President, Behavioral Health, who has been with the Company since 2019, submitted his resignation from his position with the Company, effective June 19, 2026 (“Effective Date”). Mr. Peterson intends to pursue an external career opportunity that is not competitive to the Company. (e) As a result of such resignation, all of Mr. Peterson’s unvested stock options, restricted stock units and performance based restricted stock units will terminate as of the Effective Date. Mr.

Stryker Corporation (the “Company”) announced on May 20, 2026 that William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026 and that Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026. There are no arrangements or understandings between Ms. Baculik and any person pursuant to which Ms. Baculik was selected as an officer, and no family relationships exist between Ms. Baculik and any director or executive officer of the Company. Ms. Baculik is not a party to any transaction to which the Company is or was a participant and in which Ms. Baculik has a direct or indirect material interest subject to disclosure under Item 404(a) of Regulation S-K. Biographical Information Ms.

Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026. In connection with the transition of his role, Mr. Griffith will remain employed as an Executive Vice President, a non-executive officer position from September 1, 2026 until January 31, 2027. Mr. Griffith is currently retirement eligible under the Company’s plans and policies, and thus upon his departure in January 2027 will receive the retirement benefits provided by the Company’s plans and policies, described in the Company’s filings, including the Company’s proxy statement. Appointment of Thomas Dittrich, Executive Vice President and Chief Financial Officer In connection with Mr.

On May 18, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio, and that Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026. Mr. Wall will remain an employee of the Company until September 1, 2026, to assist with the transition. Mr. Wall is entitled to and will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers as described in Medtronic’s 2025 Proxy Statement filed with the Securities and Exchange Commission on August 25, 2025.

(e) On May 14, 2026, CVS Health Corporation (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the 2026 Incentive Compensation Plan of CVS Health Corporation (the “2026 ICP”), which replaces the Company’s expiring 2017 Incentive Compensation Plan. The 2026 ICP applies to awards granted after May 14, 2026. The Management Planning and Development Committee and the Board of Directors of the Company previously approved the 2026 ICP, subject to stockholder approval.

On May 12, 2026, in connection with the previously announced appointments of Daniel Finke as Group President, Medicaid and Marketplace and Michael Carson as Group President, Medicare and Specialty, the Board of Directors determined that the following individuals are the Company's executive officers: Sarah London, Chief Executive Officer; Drew Asher, Chief Financial Officer; Daniel Finke, Group President, Medicaid and Marketplace; Michael Carson, Group President, Medicare and Specialty; Susan Smith, Chief Operations Officer; Christopher Koster, General Counsel; and Theodore Pienkos, Corporate Controller and Chief Accounting Officer. Tanya McNally continues to serve as the Company's Chief People Officer.

On May 7, 2026, the Compensation Committee of the Board of Directors of Mettler-Toledo International Inc. (the “Company”), with guidance from the Committee’s independent compensation consultant, approved the grant of 2026 long-term incentive (“LTI”) awards to the Company’s named executive officers (“NEOs”). The Committee approved a bifurcated grant structure and composition for 2026 LTI awards that will comprise 1/3 performance share units, 1/3 non-qualified stock options, and 1/3 restricted stock units, of which half will be granted in May 2026 and half will be granted in November 2026. The Committee believes that bifurcating the 2026 LTI awards into two grants and modifying the composition of each grant improves the retentive and motivational objectives of the compensation program in the current environment.

Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer On March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval. A summary of the principal features of the Plan is set forth under Proposal No. 4 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 2, 2026 (the “Proxy Statement”), which description is incorporated herein by reference. The Plan was approved by the Company's shareholders at the Company's annual meeting of the shareholders held on May 13, 2026 (the "Annual Meeting").

On May 5, 2026, Charles River Laboratories International, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the shareholders of the Company approved the Company’s 2026 Long-Term Incentive Plan (the “2026 Incentive Plan”). The Board of Directors of the Company had previously approved and adopted the 2026 Incentive Plan on March 11, 2026, subject to the approval of the shareholders of the Company. The material features of the 2026 Incentive Plan are described in detail under “Proposal 3 - Approval of the 2026 Long-Term Incentive Plan” of the Company’s Definitive Proxy Statement on Schedule 14A for the Annual Meeting filed by the Company with the Securities and Exchange Commission on March 31, 2026 (the “Proxy Statement”).

Executive Severance and Change in Control Plan and Hider Offer Letter Amendment On May 4, 2026, the Compensation and Human Capital Committee of the Board of Directors (the “Board”) of Baxter International Inc. (the “Company”) approved the Baxter International Inc. Executive Severance and Change in Control Plan (the “Severance Plan”), effective as of May 4, 2026 (the “Effective Date”). The Severance Plan supersedes the Baxter International Inc.

Approval of the Amended and Restated Long-Term Stock Incentive Compensation Program At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Edwards Lifesciences Corporation, a Delaware Corporation (the “Company”), the Company’s stockholders approved the amendment and restatement of the Company’s Long-Term Stock Incentive Compensation Program (the “Long-Term Stock Program”). The amendment approved by stockholders included an increase in the total number of shares of Edwards common stock available for issuance under the Long-Term Stock Program by 7,000,000 shares to a new total share limit of 341,500,000 shares. The complete terms of the Long-Term Stock Program amendment is qualified in its entirety by reference to the full text of the Amended and Restated Long-Term Stock Program, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

of Becton, Dickinson and Company’s (the “Company”) Current Report on Form 8-K filed with the Securities and Exchange Commission on October 15, 2025 (the “Original Form 8-K”). This Amendment should be read in conjunction with the Original 8-K.

On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations, policies or practices. The Company and the Board thank Mr. Breeden for his 18 years of service to the Company as a Director. On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date. Mr. Boulud, age 54, is the Chief Executive Officer of bioMérieux, a biotechnology company focused on in vitro diagnostics, having served in that role since June 2023. Mr.

On May 5, 2026, at the annual meeting of shareholders (the “Annual Meeting”) of Danaher Corporation (the “Company”), as further described in

On May 4, 2026, The Cooper Companies, Inc. (the “Company”) announced that, on recommendation of the Corporate Governance & Nominating Committee, the Board of Directors of the Company (the “Board”) approved an increase in the size of the Board from nine directors to ten directors effective as of July 1, 2026, and approved the appointment of Paul Keel to fill the new director position, effective as of July 1, 2026, until his successor is duly elected and qualified or until his earlier resignation or removal. The Board also approved the appointment of Mr. Keel to the Audit Committee, effective as of July 1, 2026, and concurrent with his appointment to the Board. Mr. Keel has been determined to be an independent director under Nasdaq listing standards. There are no arrangements or understandings between Mr. Keel and any other persons pursuant to which he was selected as a director.

(b) As previously disclosed, on March 31, 2026, Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary of Agilent Technologies, Inc. (the “Company”), entered into a transition and general release agreement with the Company (the “Transition Agreement”) pursuant to which Mr. DiMarco will resign from such roles upon the earlier to occur of the start date of a new Chief Legal Officer or September 30, 2026. On May 4, 2026, the Company appointed Michael Buckner as the new Chief Legal Officer and, as a result, effective on such date, Mr. DiMarco resigned from his positions as Senior Vice President, Chief Legal Officer and Secretary of the Company. In accordance with the Transition Agreement, Mr. DiMarco will remain employed as a Special Advisor in order to provide transitional assistance through December 1, 2026.

On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity. Ms. Mistras will cease to serve as Chief Financial Officer effective May 8, 2026 and will remain employed by the Company until May 22, 2026 for transition purposes. Ms. Mistras’ resignation was not related to any disagreement between Ms. Mistras and the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls, or operations. On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board. Mr.

On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position. Ms. Mistras, age 44, has served as Chief Financial Officer of Viatris, Inc. (NASDAQ: VTRS), a global pharmaceutical and healthcare corporation, since March 1, 2024. Prior to joining Viatris, Inc. as CFO-elect in January 2024, Ms. Mistras was Managing Director, Healthcare Investment Banking at Citigroup Global Markets from September 2019 to December 2023 and prior to that was Managing Director, Healthcare Investment Banking at Goldman Sachs, where she spent over 15 years in their investment banking healthcare group. In connection with her appointment as Corporate Vice President, Chief Financial Officer, Ms.

Approval of the Amendment and Restatement of the Amended and Restated 2010 Incentive Award Plan The Board of Directors (the “Board”) of Intuitive Surgical, Inc. (the “Company”) previously adopted, subject to stockholder approval, the amendment and restatement of the Company’s Amended and Restated 2010 Incentive Award Plan (the “Amended 2010 Plan”), which (i) increases the number of shares of common stock reserved for issuance pursuant to awards granted under the Amended 2010 Plan from 120,350,000 to 125,350,000, (ii) extends the term of the Amended 2010 Plan to January 29, 2036, and (iii) further specifies the treatment of awards in connection with a change in control. At the Company’s annual meeting of stockholders held on April 30, 2026 (the “Annual Meeting”), the Company’s stockholders approved the Amended 2010 Plan.

On April 30, 2026, ResMed Inc. (the “Company”) announced that Brett Sandercock, Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, will retire from his role as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer. Mr. Sandercock will continue to serve as Chief Financial Officer until May 4, 2026, immediately following which he will become Special Advisor to Mick Farrell, Chairman and Chief Executive Officer through December 31, 2026. Mr. Sandercock will continue to receive his current salary, benefits and vesting of long-term equity incentives and will remain eligible for a six month, pro-rata payment of his short-term incentive for fiscal year 2027. From January 1, 2027, through December 31, 2027, Mr. Sandercock will continue as Special Advisor to Mr. Farrell in a consulting role.

On April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”). Mr. Upadhyay has recently been named the forthcoming Chief Financial Officer of Incyte Corporation. Mr. Upadhyay will continue to serve on the Board until the time of the 2026 Annual Meeting. Mr. Upadhyay’s decision to depart from the Board was due to scheduling conflicts associated with his new role at Incyte Corporation and did not involve any disagreement with the Company on any matter relating to its operations, policies or practices. The Board intends to reduce the size of the Board to ten members following the departure of Mr. Upadhyay. Mr.

On April 22, 2026, Suketu Upadhyay informed Zimmer Biomet Holdings, Inc. (the “Company”) of his intention to resign from the position of Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain of the Company, effective as of April 28, 2026, to pursue a new professional opportunity. Mr. Upadhyay’s departure is not the result of any disagreement with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices. In connection with Mr. Upadhyay’s departure, Paul Stellato, Vice President, Controller and Chief Accounting Officer, has been appointed to act, along with continuing to serve in his current role, as the Company’s interim Chief Financial Officer, effective upon Mr. Upadhyay’s departure, until a permanent successor is named. In this role, Mr.

On April 24, 2026, Kevin Conroy was named to the Abbott Laboratories’ (“Abbott”) Board of Directors. On April 24, 2026, Abbott shareholders approved the adoption of the Abbott Laboratories 2026 Incentive Stock Program (the “2026 Program”) at the Annual Meeting of Shareholders. The 2026 Program was adopted by Abbott’s Board of Directors on February 20, 2026, subject to shareholder approval at the Annual Meeting. The 2026 Program replaces the Abbott Laboratories 2017 Incentive Stock Program, as amended and restated (the “2017 Program”), under which Abbott makes all of its equity-related incentive compensation awards.

On April 23, 2026, IQVIA Holdings Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the 2026 Incentive and Stock Award Plan (the “2026 Plan”). The material terms of the 2026 Plan are described in “Proposal No. 4 – Approval of IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 27, 2026. The 2026 Plan became effective immediately upon approval by the Company’s stockholders. The 2026 Plan replaces the IQVIA Holdings Inc. 2017 Incentive and Stock Award Plan (the “2017 Plan”) and assumes any shares remaining under the 2017 Plan as of the effective date of the 2026 Plan.

On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer. To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibilities of this role will be redistributed to James E. Bradner, Executive Vice President, Research and Development, Artificial Intelligence and Data, Murdo Gordon, Executive Vice President, Amgen Global Markets and Policy, and Peter H. Griffith, Executive Vice President and Chief Financial Officer, each effective as of June 1, 2026. Dr. Reese will remain employed as an Executive Vice President until his retirement on June 30, 2026. Departure of Executive Vice President On June 30, 2026, Dr.

On April 20, 2026, Veeva Systems Inc. ("Veeva") announced that Josh Faddis intends to retire from his role as Senior Vice President, General Counsel, effective as of November 1, 2026. At that time, Mr. Faddis intends to transition into a part-time advisor to Veeva. Veeva will appoint a successor upon Mr. Faddis' transition.

(d) On April 10, 2026, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from ten to eleven and elected Robert S. Field as a director of the Company, in each case effective immediately following the adjournment of the Humana Inc. 2026 Annual Meeting of Stockholders on April 16, 2026. The Board of Directors has determined Mr. Field qualifies as an independent director under the New York Stock Exchange’s director independence standards. Mr. Field will be compensated in accordance with the Company’s director compensation program, the components of which are disclosed in the Company’s proxy statement relating to 2026 Annual Meeting of Stockholders filed with the U.S. Securities and Exchange Commission on March 6, 2026. In accordance with this program, Mr.

On April 6, 2026, Richard E. Byrd, Executive Vice President and President of the Interventional segment of Becton, Dickinson and Company (“BD”), informed BD of his intention to retire. Mr. Byrd will remain in his role through June. BD intends to name a successor to Mr. Byrd prior to his retirement date.

On March 31, 2026, STERIS plc (the “Company”) and Michael J. Tokich, the Company’s former Chief Financial Officer, entered into an amendment (the “Amendment”) to the Transition Agreement, dated August 5, 2025, between the Company and Mr. Tokich (the “Agreement”). In general, the Agreement governs the compensation and benefits that Mr. Tokich receives for his post-executive employment with the Company. Pursuant to the Amendment, Mr. Tokich’s employment with the Company as a senior financial advisor will be extended on a part-time basis from April 1, 2026 through March 31, 2027 (the “Extended Advisor Period”). The Amendment also provides that, during the Extended Advisor Period, Mr. Tokich’s annual base salary will be reduced to $60,000, Mr.

(e) On March 31, 2026, Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary of Agilent Technologies, Inc. (the “Company”), entered into a transition and general release agreement with the Company (the “Transition Agreement”) pursuant to which Mr. DiMarco will resign from such roles upon the earlier to occur of the start date of a new Chief Legal Officer or September 30, 2026. In any event, Mr. DiMarco will continue as a Special Advisor in order to provide transitional assistance through December 1, 2026. While serving as a Special Advisor, Mr. DiMarco will be paid a base salary at the annualized rate of $350,000, will remain eligible to participate in the Company’s group health and welfare plans and will continue vesting in outstanding Company equity awards in accordance with their terms, however, Mr.

(b) On April 2, 2026, each of Drs. Frances Arnold, Robert S. Epstein and Gary S. Guthart notified the Board of Directors (the "Board") of Illumina, Inc. (the "Company") of her or his intention to retire as a director of the Company, effective as of May 21, 2026 (the date of the Company’s 2026 annual meeting of stockholders). The retirements of Drs. Arnold, Epstein and Guthart are not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.

2026 Annual Incentive Bonus Performance Goals On March 26, 2026, the Compensation Committee of the Board of Directors (the “Committee”) approved specific bonus formulae for the determination of annual incentive compensation for the Company’s executive officers for the year ending December 31, 2026, pursuant to the 2022 Executive Incentive Plan which was adopted by the Committee in March, 2022 (the “Plan”). Under the formulae approved by the Committee, each of the Company’s executive officers was assigned a percentage of such executive officer’s 2026 base salary as a target bonus based upon corporate performance criteria. The corporate performance criteria target bonus award indicated below for Mr. Marc D. Miller is stipulated in his employment agreement. Mr. Alan B.

On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company’s Board since 2022, was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Board thanks Dr. Schaffert for her thoughtful counsel and meaningful contributions to the Company during her service. 2

On March 24, 2026, IDEXX Laboratories, Inc. (“IDEXX”) and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 (the “Separation Date”) and will continue to provide advisory services on an as-needed basis until July 13, 2026 (the “Final Employment Date”). IDEXX and Dr. Hunt entered into a separation letter agreement (the “Separation Agreement”) to memorialize the terms of Dr. Hunt’s advisory role and subsequent departure. Pursuant to the Separation Agreement, IDEXX will pay to Dr. Hunt separation benefits in the form of (i) salary continuation for 104 weeks following the Separation Date, in the aggregate amount of $1,230,000; (ii) Dr.

On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa’s title was changed to Executive Vice President and Head of U.S. Commercial. Dr. Cagnoni replaces William J. Meury as President, Incyte. Mr. Meury remains Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Meury, Dr. Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the “Impacted Executives”. There were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes.

(b) On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.

Effective March 18, 2026, the Board of Directors (the Board) of Centene Corporation (the Company) appointed Theodore Pienkos, 44, a registered CPA, to serve as the Company's Corporate Controller and Chief Accounting Officer. Mr. Pienkos previously has served as the Company's Deputy Corporate Controller since August 2024. Prior to that, he served as Vice President of Finance & Accounting from August 2017 to August 2024, and he has held other accounting roles of increasing importance with Centene since March 2011. Before joining Centene, Mr. Pienkos served as an auditor for KPMG LLP from August 2004 to March 2011. He holds a BA and MA in Accounting from the University of Northern Iowa. In connection with this appointment, he will receive a base salary of $440,000 and have a target bonus of 60% of the base salary.

On March 17, 2026, Gregory B. Kenny notified Cardinal Health, Inc. (the “Company”) of his decision to retire from the Board of Directors (the “Board”), all committees thereof and from his position as Board Chair, effective March 20, 2026. Mr. Kenny’s decision to retire was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies or practices. The Board appointed Patricia A. Hemingway Hall, who is a current director, as Board Chair, effective immediately.

(d): On March 18, 2026, the Board of Directors (the “Board”) of CVS Health Corporation (“CVS Health” or the “Company”) elected John E. Gallina to serve on the Board, effective March 19, 2026. Mr. Gallina, age 66, is the former Executive Vice President and Chief Financial Officer (“CFO”) of Elevance Health, Inc. (“Elevance”; NYSE: ELV) a leading health benefits provider. Mr. Gallina served in the CFO role for Elevance from June 2016 through November 1, 2023, then served as EVP and Advisor to the CEO from November 1, 2023 until May 2024, when he retired. During the course of his nearly 30-year career with Elevance, Mr. Gallina held a number of finance and audit-related roles, including Chief Accounting Officer and Chief Risk Officer. Prior to joining Elevance, Mr. Gallina was a senior audit manager and a certified public accountant at Coopers & Lybrand. Mr.

On March 13, 2026, the Board of Directors (the “Board”) of GE HealthCare Technologies Inc. (the “Company”) appointed Kevin A. Lobo to serve as a director of the Company, effective immediately. Mr. Lobo’s term will expire at the Company’s 2026 Annual Meeting of Stockholders. The Board also appointed Mr. Lobo as a member of the Talent, Culture, and Compensation Committee of the Board, effective immediately. Mr. Lobo will receive compensation in accordance with the Company’s compensation program for non-employee directors, which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025. The Company will also enter into an indemnification agreement with Mr. Lobo.

On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026. Mr. Cleary’s decision to retire from his position was not the result of a disagreement on any matter related to the Company’s operations, policies or practices.

Transition of Joel Grade as CFO; Appointment of Anita Zielinski as Interim CFO On March 16, 2026, Baxter International Inc. (the “Company”) announced that, as of such date (the “Transition Date”), Joel Grade’s service as Executive Vice President and Chief Financial Officer (“CFO”) of the Company has ceased and, as of such date, Mr. Grade has transitioned into a non-executive officer role and will continue employment with the Company in an advisory capacity through April 30, 2026. Subject to Mr.

(d) On March 9, 2026, the Board of Directors (the “Board”) of Quest Diagnostics Incorporated (the “Company”), after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. The Board appointed Mr. Wentworth to serve on the Board’s Compensation and Leadership Development Committee and the Board’s Quality and Compliance Committee. The Board determined that Mr. Wentworth is an independent director pursuant to the New York Stock Exchange listing standards and the Company’s independence guidelines, as set forth in its corporate governance guidelines. Mr. Wentworth will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices. As part of that compensation, Mr.

On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May, 2026. The Company has initiated a search to identify the Company’s next Chief Legal Officer.

Today, March 9, 2026 , West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6, 2026 of his intent to retire from those positions once his successor has been hired in order to ensure a smooth transition. The Board is engaging a leading executive recruiting firm to assist with the search for a successor and expects this transition to occur in the second half of 2026.

(b) On March 5, 2026, Rodney Gonsalves, informed Agilent Technologies, Inc. ("Agilent") that he would retire from his position as Agilent’s Vice President, Corporate Controller and Principal Accounting Officer in January 2027, the exact date to be determined at a later time. Mr. Gonsalves' departure is not related to any disagreement with Agilent on any matter relating to its accounting practices, financial statements, internal controls, or operations and the advance notice of his retirement allows lead time for Agilent to conduct a comprehensive search for his replacement and for Mr. Gonsalves to assist with the orderly transition of duties to his successor.

Retirement of Principal Financial Officer On March 3, 2026, Britt J. Vitalone, the company’s Executive Vice President and Chief Financial Officer, gave notice of his intention to retire from that role. Mr. Vitalone’s last day as our CFO will be May 28, 2026, and he will remain an employee through July 1, 2026. Mr. Vitalone thereafter will serve as a non-employee advisor to the company as described below under the heading Advisory Arrangement . Appointment of Principal Financial Officer On March 4, 2026, Kenny K. Cheung was appointed as the company’s Executive Vice President and Chief Financial Officer, effective as of May 29, 2026, for the term of office provided by Article IV of the company’s By-Laws. Mr. Cheung, age 44, most recently was employed by Sysco Corporation.

On March 2, 2026, Mary Scherer, Senior Vice President and Chief Accounting Officer, notified Cardinal Health, Inc. (the “Company”) that she intends to retire in February 2027. The Company will initiate a search process to identify her successor. Ms. Scherer will continue to serve as Chief Accounting Officer until her successor is identified and onboarded to ensure a smooth transition.

On February 27, 2026, Insulet Corporation (the “Company”) entered into a severance agreement and release (the “Severance Agreement”) with Ana M. Chadwick, the Company’s former Chief Financial Officer. The Severance Agreement does not provide for any material compensation or benefits terms that differ from, or are in addition to, those previously disclosed in the Company’s Form 8-K filed on September 16, 2025 and the Company’s Amended and Restated Executive Severance Plan, filed as an exhibit to the Form 8-K filed on April 28, 2025. The Severance Agreement includes standard provisions relating to the release of legal claims, mutual non-disparagement obligations, and requirements for Ms.

Chief Executive Officer Succession On February 25, 2026, the Board of Directors (the “Board”) of The Cigna Group (the “Company”) appointed Mr. Brian C. Evanko as Chief Executive Officer (“CEO”) of the Company, effective July 1, 2026. Mr. Evanko will succeed Mr. David M. Cordani, who will retire as the CEO of the Company effective July 1, 2026. Mr. Cordani has been appointed Executive Chair of the Board, effective July 1, 2026. Mr. Evanko, 49, has served as President and Chief Operating Officer, The Cigna Group, since March 2025, Executive Vice President and Chief Financial Officer, The Cigna Group and President and Chief Executive Officer, Cigna Healthcare from January 2024 to March 2025; Executive Vice President and Chief Financial Officer, The Cigna Group from January 2021 to January 2024; President, Government Business from November 2017 to January 2021; and President, U.S.

As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026. In connection with his retirement, on July 25, 2025, the Board appointed Mr. Sayer as Executive Chairman of the Board, effective January 1, 2026, to provide ongoing leadership and strategic guidance to the Company. As previously reported on the Current Report on Form 8-K filed on September 15, 2026, effective September 14, 2025, Mr. Sayer took a temporary leave of absence. On February 27, 2026, Mr. Sayer notified the Company of his plans to return from his temporary leave of absence, effective March 2, 2026. Upon his return, Mr.

On February 24, 2026, the Board of Directors appointed Dennis Stankiewicz, age 48, to the position of Chief Accounting Officer of UnitedHealth Group Incorporated (the “Company”) effective March 2, 2026. Mr. Stankiewicz will continue to serve as the Company’s Corporate Controller, a position he has held since April 17, 2023. Mr. Stankiewicz joined the Company in August 2016 and served as its General Auditor. Prior to joining the Company, Mr. Stankiewicz was a partner with Deloitte & Touche, LLP and has more than 24 years of professional experience. In connection with this appointment, the Compensation and Human Resources Committee of the Company approved the following compensation arrangements for Mr. Stankiewicz: • Receive an annual base salary of $550,000.

On February 26, 2026, Elevance Health, Inc. (the “Company”) announced certain management changes. Among these changes, Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon, effective May 4, 2026, to devote more time to family commitments. Mr. Haytaian will serve the Company as Special Advisor through December 31, 2026, to support an orderly leadership transition and ensure continuity across Carelon’s operations and client and partner relationships. Mr. Haytaian’s decision is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. A copy of the press release dated February 26, 2026, is furnished as Exhibit 99.1 to this report.

On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately. Mr. Osterloh will hold office for a term expiring at the 2026 annual meeting of Dexcom’s stockholders (the “2026 Annual Meeting”). The Board also appointed Mr. Osterloh to serve as a member of the Compensation Committee and the Technology Committee of the Board, effective immediately. There is no arrangement or understanding between Mr. Osterloh and any other persons pursuant to which Mr. Osterloh was selected as a director. Mr.

2026 Executive Officer Performance Excellence Program On February 24, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of HCA Healthcare, Inc. (the “Company”) adopted the 2026 Executive Officer Performance Excellence Program (the “Executive Officer PEP”). Under the Executive Officer PEP, the executive officers of the Company shall be eligible to earn performance awards based upon the achievement of certain specified performance targets. The Executive Officer PEP award opportunities for the Company’s executive officers are weighted (i) 80% for the achievement of certain EBITDA (as defined in the Executive Officer PEP) targets and (ii) 20% for the achievement of targets associated with certain quality metrics.

On February 23, 2026, the Compensation and Human Resources Committee of the Board of Directors of UnitedHealth Group Incorporated (the “Company”) amended the stock option granted to Stephen Hemsley on May 14, 2025 (previously disclosed in the Company’s Form 8-K filed on May 14, 2025). The amendment adds a two-year share holding requirement following a three-year cliff vesting. Specifically, Mr. Hemsley must hold any net shares acquired upon exercise of the stock option until May 14, 2030, except in the event of death or disability. All other terms of the stock option remain unchanged.

On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of stockholders, in each case, effective February 18, 2026. The Board further appointed Ms. Smith to serve as a member of the Audit Committee and the Nominating and Governance Committee of the Board, and Mr. Weber to serve as a member of the Executive Compensation and Human Resources Committee and the Risk, Science and Technology Committee of the Board, in each case, effective as of February 23, 2026.

On February 18, 2026, the Company announced the appointment of Glenn Coleman as its Corporate Executive Vice President and Chief Financial Officer. Mr. Coleman will join the company with a tentative start date of April 6, 2026. Mr. Coleman, 58, will join Charles River with over 30 years of strong financial and operational management experience, including more than a decade of senior leadership roles in the healthcare sector. Most recently since 2024, Mr. Coleman has been serving as Chief Financial Officer and Chief Administrative Officer of Premier, Inc., a $1-billion healthcare services business. Prior to this role, he was the CFO of two public companies, DENTSPLY SIRONA Inc. and Integra Life Sciences Holdings Corporation. Mr. Coleman served as Executive Vice President and CFO at DENSTPLY from 2022 to 2024.

(b) On February 13, 2026, Ms. M. Anne Szostak provided IDEXX Laboratories, Inc. (the “Company”) notice of her intention to retire from the Board of Directors (the “Board”) effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) to be held on May 12, 2026. Ms. Szostak’s decision to retire from the Board does not arise from any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, practices or otherwise. The Company thanks Ms. Szostak for her extraordinary service, contributions and leadership during her tenure as a member of the Board since 2012. In accordance with the Company’s amended and restated by-laws, the Board reduced the size of Class III, effective upon Ms.

Appointment of Michael R. McDonnell On February 10, 2026, Baxter International Inc. (the “Company”) appointed Michael R. McDonnell to its Board of Directors (the “Board”), effective February 13, 2026. Mr. McDonnell has also been appointed to serve as a member of the Audit Committee. Michael McDonnell served as the Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He also served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc. (f/k/a Quintiles IMS) from December 2015 through July 2020. Prior to that, Mr. McDonnell served as the Executive Vice President and Chief Financial Officer of Intelsat S.A.

On February 11, 2026, Caroline Dorsa, Chair of the Biogen Inc. (“Biogen” or the “Company”) Board of Directors (the “Board”) announced that she would not stand for re-election to the Board at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Ms. Dorsa’s decision to not stand for reelection was not related to any disagreement with the Board or the Company on any matter relating to its operations, policies or practices.

Officer Transition On February 11, 2026, Bio-Techne Corporation (the “Company”) announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. In addition, the Company announced the appointment of Mr. Steve Crouse, age 52, as President, Diagnostics and Spatial Biology Segment (“DSS President”) effective March 1, 2026. Mr. Crouse currently serves as Senior Vice President of Bio-Techne’s Analytical Solutions Division.

On February 5, 2026, Jessica L. Mega notified Danaher Corporation’s (“Danaher”) Board of Directors (“Board”) of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega’s decision was not the result of any disagreement with Danaher on any matter relating to Danaher’s operations, policies or practices.

In connection with the completion of the Transactions, and effective as of the Closing, Claire M. Fraser, Ph.D., resigned as a director of the Company and was appointed to the Waters board of directors. As a result of Dr. Fraser’s resignation, the size of the board of directors of the Company was reduced to twelve directors. The board of directors of the Company currently consists of William M. Brown, Carrie L. Byington, R. Andrew Eckert, Gregory J. Hayes, Jeffrey W. Henderson, Robert L. Huffines, Christopher Jones, Thomas E. Polen, Timothy M. Ring, Bertram L. Scott, Joanne Waldstreicher and Jacqueline Wright.

Appointment of New Director In connection with the closing of the Transactions and in accordance with the terms of the Merger Agreement, the board of directors (the “Board”) of Waters increased the size of the Board from 10 to 11 members and appointed Claire M. Fraser, Ph.D. to the Board, effective February 9, 2026, to fill the vacancy so created. Dr. Fraser will serve as a director until Waters’ 2026 annual meeting of stockholders (the “2026 AGM”) or until her earlier resignation, death or removal. The Board has determined that Dr. Fraser meets the independence standards established under the New York Stock Exchange corporate governance listing standards. There are no related party transactions between Waters and Dr. Fraser that would require disclosure under Item 404(a) of Regulation S-K. Dr.

Labcorp Holdings Inc. (the “Company”) today announced that on February 6, 2026, the Company’s Board of Directors (the “Board”) appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026. In connection with Dr. Sampson’s appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee. Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company’s director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025. Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus. Before joining the CU Anschutz School of Medicine, Dr.

On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Mr. Fujimori has served as a member of the Board of Directors (the “Board”) of the Company since July 2016 and currently serves as the chair of the Risk, Science and Technology Committee. Mr. Fujimori will continue to serve as a director and in his committee roles until the 2026 Annual Meeting. Mr. Fujimori’s decision not to stand for re-election at the 2026 Annual Meeting is not the result of any disagreement with the Company. The Board and Nominating and Governance Committee regularly review the size and composition of the Board and will continue to evaluate whether adding directors to the Board following Mr. Fujimori’s departure is in the best interest of the Company.

On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026. Mr. Roman will remain an employee of the Company until April 1, 2026 for transitional purposes. In connection with his departure from the Company, Mr. Roman will be eligible to receive separation payments equal to the sum of his base salary plus target bonus and a pro rata bonus for 2026, consistent with severance benefits paid to similarly situated executives. Mr. Roman would also execute a customary release of claims. On February 3, 2026, the Company also announced that Matthew Maletta will join the Company as Chief Legal Officer on February 9, 2026. Mr.

Executive Officer Severance Plan On January 27, 2026, the Board of Directors of Becton, Dickinson and Company (“BD”) approved and adopted the BD Executive Severance Plan (the “Severance Plan”), effective January 27, 2026. The Severance Plan provides severance benefits to management employees designated at job level J-G9 (including the Company’s named executive officers and executive officers) upon a termination of their employment by the Company without Cause (as defined in the Severance Plan), other than due to death or disability, and who execute and do not revoke a general release of claims.

Director Appointment On January 20, 2026, the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”) appointed Ellen G. Cooper to serve on the Board (the “Appointment”), effective immediately. In connection with the Appointment, the Board increased from ten to eleven members in accordance with the Company’s Amended and Restated Bylaws. Ms. Cooper will receive the same benefits and compensation as the other non-employee directors on the Board pursuant to the Company’s Compensation Policy for Non-Employee Directors, as described on pages 40 to 41 of the Definitive Proxy Statement on Schedule 14A filed by the Company with the Securities and Exchange Commission on January 23, 2025.

On January 16, 2026, the Board of Directors of Mettler-Toledo International Inc. (the "Company") appointed Michael J. Tokich as a director of the Company, effective February 5, 2026, and determined Mr. Tokich qualifies as an "independent director" for purposes of the New York Stock Exchange listing standards. The Board of Directors has not yet determined on which Board committees, if any, Mr. Tokich will serve. In connection with the appointment, the Board of Directors resolved to increase its size from nine directors to ten directors, effective February 5, 2026. Mr. Tokich’s compensation for his services as a director will be consistent with that of the Company's other independent directors, as described in the Company's definitive proxy statement filed with the Securities Exchange Commission on March 17, 2025. There are no arrangements or understandings between Mr.

CEO Transition. On January 11, 2026, Jonathan (Jay) Mazelsky notified IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) of his intent to step down as the Company’s President and Chief Executive Officer effective as of May 12, 2026 (the “Transition Date”) and retire from the Company and the Company’s Board of the Directors (the “Board”) immediately following the Company’s annual meeting of shareholders in May 2027 (the “Retirement Date”). On January 13, 2026, the Company announced that effective as of the Transition Date Mr. Mazelsky will transition to the role of Executive Chair of the Board and Michael (Mike) Erickson, PhD, will assume the role of President and Chief Executive Officer of the Company and join the Board as a Class II Director. In his capacity as President and Chief Executive Officer, Dr. Erickson will serve as the Company’s principal executive officer. Mr.

On January 8, 2026, Mark Bezjak, a named executive officer in the 2025 proxy statement of Zimmer Biomet Holdings, Inc. (the “Company”), informed the Company that he will resign his employment, including all officer positions with the Company and its affiliates, effective as of January 16, 2026, to pursue another business opportunity. As previously reported, Mr. Bezjak ceased to be an executive officer of the Company on July 1, 2025.

Executive Leadership Changes On January 10, 2026, the Board of Directors (the “Board”) of Henry Schein, Inc. (the “Company”) appointed Mr. Frederick Lowery as Chief Executive Officer of the Company, effective March 2, 2026 (the “Effective Date”). In connection with Mr. Lowery’s appointment, the Board expanded the size of the Board from 14 to 15 members and appointed Mr. Lowery to fill the resulting vacancy, in each case, effective as of the Effective Date. Mr. Lowery, 54, comes to the Company from Thermo Fisher Scientific Inc., where he has most recently served as Executive Vice President and President, Laboratory Products and BioProduction. Prior to this role, he served as Senior Vice President and President, Customer Channels since January 2021. He joined Thermo Fisher Scientific Inc.

Each of Michel Lagarde and Frederick M. Lowery have notified Thermo Fisher Scientific Inc. (the “Company”) of their decisions to leave the Company to pursue other opportunities. Mr. Lagarde, who has served as Executive Vice President and Chief Operating Officer of the Company since 2021 will depart on March 31, 2026, and Mr. Lowery, who has served as an Executive Vice President of the Company since 2024 will depart on February 28, 2026. Effective March 1, 2026, Thermo Fisher Scientific will update its organizational structure and leadership team. Marc N. Casper will become Chairman and Chief Executive Officer. Gianluca Pettiti, currently an Executive Vice President, will be promoted and transition to the role of President and Chief Operating Officer.

Chief Executive Officer Transition On January 8, 2026, the Board of Directors (the “Board”) of Charles River Laboratories International, Inc. (the “Company”) announced a leadership transition plan. Mr. James C. Foster, our current Chairman of the Board, President and Chief Executive Officer, intends to step down as Chief Executive Officer and Chairman of the Board, and Ms. Birgit Girshick, our Chief Operating Officer, will be appointed as our Chief Executive Officer, each effective as of May 5, 2026 (the “Transition Date”). Following the Transition Date, it is expected that Mr. Foster will remain a non-executive director of the Board. Dr. Martin Mackay, current Lead Independent Director, is expected to become Chair of the Board, effective as of the Transition Date. In addition, Ms.

On January 4, 2026, Everett Cunningham, Chief Commercial Officer, notified Illumina, Inc. that he will be resigning effective as of January 16, 2026.

Amended and Restatement Employment Agreement of Mr. Marc D. Miller On December 30, 2025, the Compensation Committee of the Board of Directors of Universal Health Services, Inc. (the “Company”) approved amendments to the existing employment agreement between Mr. Marc D. Miller, the Company’s Chief Executive Officer (“CEO”) and President, and UHS of Delaware, a wholly owned subsidiary of the Company and, the employer of record for the Company’s management employees. The obligations of UHS of Delaware under the amended and restated employment agreement (the “A&R Employment Agreement”) are, other than as set forth herein, substantially the same as the existing employment agreement and are guaranteed by the Company. The Compensation Committee also approved an amendment to the Company guaranty to make certain conforming changes. Pursuant to the terms of the A&R Employment Agreement, Mr.

The information in Item 1.01 is incorporated by reference herein. In connection with the Agreement, following the recommendation of the Nominating Committee, on December 22, 2025, the Board appointed Mr. Rosebrough to the Board and to the Nominating Committee, effective January 3, 2026. Mr. Rosebrough will be paid the same compensation received by other non-management directors on the Board, which is more fully described under the caption “Compensation of Directors” in the Company’s proxy statement on Schedule 14A filed with the Securities and Exchange Commission on February 19, 2025, as may be adjusted by the Board from time to time. Other than the Agreement, there is no other arrangement or understanding pursuant to which Mr. Rosebrough will be appointed as a director of the Company. There are no family relationships between Mr.

On December 23, 2025, Henry Schein, Inc. (the “Company”) issued a press release announcing that its Board of Directors expects to name the Company’s next Chief Executive Officer by mid-January 2026 and that Stanley M. Bergman will continue in his role as CEO and Chairman of the Company until a successor CEO assumes the position. In connection with the announcement, the Company and Mr. Bergman entered into a letter agreement (the “Letter Agreement”) to extend Mr. Bergman’s Amended and Restated Employment Agreement dated as of November 28, 2022 by and between the Company and Mr. Bergman (the “Employment Agreement”) for a term through the earlier of (a) the date of commencement of employment of a new Chief Executive Officer of the Company and (b) the date following the thirtieth (30 th ) day after Mr.

As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date. Mr. Leach has served as Dexcom’s interim principal executive officer in addition to his other duties since Mr. Sayer’s medical leave of absence, as previously reported on the Current Report on Form 8-K filed September 15, 2025. In connection with Mr. Leach’s promotion to Chief Executive Officer, effective as of January 1, 2026, on December 19, 2025, Mr.

Effective January 1, 2026, Brian E. Miller, Ph.D., will transition from his role as Chief Digital Officer of Intuitive Surgical, Inc. (the “Company”) and begin serving as Head of Digital and AI Strategy of the Company. In this role, Dr. Miller will no longer be reporting directly to the Company’s Chief Executive Officer.

Compensatory Arrangements of Certain Officers Approval of Amended and Restated Annual Incentive Plan. On December 11, 2025, the Committee approved the amendment and restatement of the Company’s Annual Incentive Plan (the “Plan”), effective January 1, 2026, except as otherwise specified therein. The Plan was revised to clarify the definition of “for Cause” termination, expand eligibility for a prorated annual award payment following retirement if certain age and service requirements are met, augment the language relating to compensation recoupment, expand eligibility for award payments for certain terminations “without Cause”, increase the maximum award for participants, and make additional clarifying language changes, as set forth in the Plan.

(b) and (e) On December 16, 2025, Humana Inc. (the “Company”) announced that after a successful 29-year career at the Company, George Renaudin, Insurance Segment President and member of the Company’s Enterprise Leadership Team, will retire by the third quarter of 2026 (the “Transition Date”). Mr. Renaudin has agreed to serve in an advisory capacity to the Company after his transition date. In connection with his advisory service, Mr. Renaudin entered into an agreement with the Company (the “Agreement”), the material terms of which are summarized below. The payments and benefits to which Mr. Renaudin is entitled under the Agreement are generally subject to his compliance with the terms and conditions of the Agreement. Pursuant to the terms of the Agreement, Mr.

On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the “Company”), notified the Company of his intention to retire, effective on April 1, 2026.

On December 9, 2025, Brian G. Andrews, Executive Vice President, Chief Financial Officer and Treasurer of The Cooper Companies, Inc. (the “Company”), assumed the role of principal accounting officer of the Company from Agostino Ricupati, who will continue in the role of the Company’s Senior Vice President, Tax. Mr. Andrews has served as the Company’s Executive Vice President since 2020 and Chief Financial Officer and Treasurer since 2018. Additional biographical information regarding Mr. Andrews is included in the Company’s most recent proxy statement, filed with the Securities and Exchange Commission on February 19, 2025. There are no arrangements or understandings between Mr. Andrews and any other persons pursuant to which he assumed the additional responsibilities of principal accounting officer.

On December 12, 2025, Nita Ahuja, M.D. was named to the Abbott Laboratories’ (“Abbott”) Board of Directors.

Director Retirement On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately. Mr. Hoppenot, the former Chairman and Chief Executive Officer of the Company, has been a member of the Company’s Board of Directors since 2014. 2

On December 10, 2025, the board of directors of Veeva Systems Inc. ("Veeva”) appointed Vipin Kondath as Veeva’s principal accounting officer, effective December 12, 2025. Vipin Kondath, age 50, has served as Veeva’s VP, Corporate Controller since April 2022. From August 2019 to March 2022, he served as Veeva’s Senior Director of Revenue Accounting. Mr. Kondath holds a Bachelor of Commerce degree from Mahatma Gandhi University, and is a chartered accountant from India and a certified public accountant in the State of California. Mr. Kondath also entered into Veeva’s standard form of indemnification agreement and there was no change to his compensation arrangements as a result of the appointment. There are no family relationships between Mr. Kondath and any of Veeva’s directors or executive officers. Mr.

On December 10, 2025, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with a term expiring at the Company’s 2028 annual meeting of shareholders. The Board also appointed Ms. Schulman to its Audit and Finance Committees. There is no arrangement or understanding between Ms. Schulman and any other person pursuant to which she was elected to the Board, and Ms. Schulman has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended. The Board has determined that Ms.

On December 5, 2025, Dr. D. Gary Gilliland notified the Board of Directors (the “Board”) of Labcorp Holdings Inc. (the “Company”) of his decision to retire from the Board, effective December 31, 2025.

On August 4, 2025, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of David Simmons to the Board of Directors of the Company (the “Board”). At the time of the Initial 8-K, the Board had not determined the committee(s) to which Mr. Simmons would be named. This Amendment No. 1 to the Initial 8-K is being filed to report that on December 4, 2025, the Board appointed Mr. Simmons to serve on the Compensation Committee and the Science and Technology Committee, effective immediately after the 2025 annual meeting of shareholders.

On December 4, 2025, Robert S. Weiss, Chairman of the Board (“Chairman”) and a member of the Board of Directors (the “Board”) of The Cooper Companies, Inc. (the “Company”), notified the Company of his resignation as Chairman, effective as of January 2, 2026. Mr. Weiss’ resignation as Chairman was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Weiss will continue to serve as a member of the Board following his resignation as Chairman and will stand for reelection at the Company’s 2026 Annual Meeting of Stockholders. The Board appointed Colleen E. Jay as Chairman, effective immediately following the resignation of Mr. Weiss as Chairman on January 2, 2026. Ms. Jay has served as a member of the Board since 2016 and is currently the Chairman of the Organization & Compensation Committee.

Stryker Corporation (the “Company”) announced on December 4, 2025 that Spencer Stiles, who currently serves as Group President, Orthopaedics, has been appointed President and Chief Operating Officer of the Company effective January 1, 2026. Dylan Crotty, who currently serves as President, Instruments, has been promoted to succeed Mr. Stiles as Group President, Orthopaedics effective January 1, 2026. There are no arrangements or understandings between Mr. Stiles or Mr. Crotty and any person pursuant to which Mr. Stiles or Mr. Crotty were selected as an officer, and no family relationships exist between Mr. Stiles nor Mr. Crotty and any director or executive officer of the Company. Neither Mr. Stiles nor Mr. Crotty is a party to any transaction to which the Company is or was a participant and in which Mr. Stiles or Mr.

DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. In connection with their appointments to the Board, effective December 1, 2025, Mr. Huffines and Ms. Wright will each receive restricted stock units valued at $33,575, representing a prorated grant from the effective date of their election to the Board through BD’s 2026 Annual Meeting of Shareholders. Information regarding the compensation of the non-management members of the Board is included under the caption “Non-Management Director Compensation” in BD’s proxy statement relating to its 2025 Annual Meeting of Shareholders.

Labcorp Holdings Inc. (the “Company”) today announced that on November 20, 2025, the Company’s Board of Directors (the “Board”) appointed Victor Bulto as a member of the Board, effective December 1, 2025. Mr. Bulto will be entitled to receive compensation for his service on the Board consistent with the Company’s director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025. Mr. Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, serving in each role since April 2022. In his more than two decades of experience at Novartis, Mr. Bulto has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe. Mr.

Appointment of Scott Gottlieb, M.D. as independent director On November 18, 2025, UnitedHealth Group Incorporated (the “Company”) announced the appointment of Scott Gottlieb, M.D. to serve as an independent director of the Company, effective immediately. Dr. Gottlieb has not yet been appointed to any committees of the Board of Directors. Dr. Gottlieb served as FDA commissioner from 2017 to 2019, where he became known for promoting transparency, strengthening patient safety and widening consumer choice. He led initiatives to modernize regulations to help foster medical innovation, promote competition in the pharmaceutical market, confront the opioid epidemic and curb youth tobacco use. In addition to his FDA service, Dr. Gottlieb has held roles at the Centers for Medicare & Medicaid Services and on the Federal Health Information Technology Policy Committee.

On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025. Dr. Bertozzi, 59, is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology at Stanford University, and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi will serve on both the Board's Science and Technology Committee and the Ethics and Compliance Committee and will stand for election by Company shareholders at the Company’s annual meeting in May 2026. The Board has determined that Dr. Bertozzi is independent under applicable standards of the New York Stock Exchange and the Company’s director independence guidelines. There are no arrangements or understandings between Dr.

Richard Sulpizio did not seek re-election at the Annual Meeting (as defined below); his term expired on November 19, 2025 at the conclusion of the Annual Meeting, creating a vacancy on our board of directors. On November 19, 2025, our board of directors approved reducing the number of directors serving on our board from twelve (12) to eleven (11). ResMed Inc. 2009 Incentive Award Plan On November 19, 2025, at the 2025 annual meeting of stockholders of ResMed Inc. (the “Annual Meeting”), our stockholders approved an amendment and restatement (the “2009 Plan Amendment”) of the ResMed Inc. 2009 Incentive Award Plan, as Amended and Restated (the “2009 Plan”) and as noted in

On November 19 , 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025. Ms. Telman’s employment with the Company will terminate later in the month.

(i) 2026 Annual Bonus Plan On November 18, 2025, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2026 Annual Bonus Plan effective for the performance year of January 1, 2026 through December 31, 2026 (the “2026 Annual Bonus Plan”). As part of the Company’s overall compensation program, the 2026 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company’s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics.

On November 17, 2025, Kristine Diamond, Chief Accounting Officer, informed Veeva Systems Inc. (“Veeva”) of her decision to resign from her position effective as of December 11, 2025. Upon Ms. Diamond’s departure, Brian Van Wagener, Chief Financial Officer of Veeva, will serve as principal accounting officer until a replacement is named.

DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On November 17, 2025, Robert L. Huffines and Jacqueline Wright were elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”), effective December 1, 2025. At that time, the size of the Board will expand from twelve to fourteen members. Upon joining the Board, Ms. Wright will serve as a member of both the Audit Committee and the Compensation and Human Capital Committee of the Board and Mr. Huffines will serve as a member of both the Audit Committee and the Corporate Governance and Nominating Committee of the Board. BD’s Board has determined that each of Ms. Wright and Mr. Huffines is independent under the rules of the New York Stock Exchange and the independence guidelines contained in BD’s Statement of Corporate Governance Principles.

On November 5, 2025, Alok Sonig notified Baxter International Inc. (the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry.